Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
Ajouter des filtres








Gamme d'année
1.
Ann. hepatol ; 16(2): 255-262, Mar.-Apr. 2017. tab, graf
Article Dans Anglais | LILACS | ID: biblio-887230

Résumé

ABSTRACT Background. Hepatocellular carcinoma (HCC) is the most common malignancy that develops in cirrhotic livers. Its clinical and epidemiological characteristics and mortality rates vary according to geographical region. The objective of this study was to evaluate the clinical profile, epidemiological characteristics, laboratory parameters, treatment and survival of patients with HCC. Material and methods. Patients with HCC seen between 2000 and 2012 were studied. The Kaplan-Meier method was used for survival analysis according to variables in question. Results. The study included 247 patients with a mean age of 60 ± 10 years. There was a predominance of males (74%). The main etiologies of HCC were HCV infection (55%), excessive alcohol consumption (12%), and HBV infection (8%). Liver cirrhosis was present in 92% of cases. The mean tumor number and diameter were 2 and 5 cm, respectively. Patients meeting the Milan criteria corresponded to 43% of the sample. Liver transplantation was performed in 22.4% of patients of the Milan subset and in 10% of the whole sample. The overall mean survival was 60 months, with a 1-, 3- and 5-year survival probability of 74%, 40% and 29%, respectively. Lower survival was observed among patients with alcoholic etiology. Survival was higher among patients submitted to liver transplantation (P < 0.001), TACE (P < 0.001), or any kind of treatment (P < 0.001). However, no difference was found for surgical resection (P = 0.1) or sorafenib (P = 0.1). Conclusion. Patients with HCC were mainly older men diagnosed at an advanced stage. Treatment was associated with better overall survival, but few patients survived to be treated.


Sujets)
Humains , Transplantation hépatique , Chimioembolisation thérapeutique , Carcinome hépatocellulaire/thérapie , Techniques d'ablation , Hépatectomie , Tumeurs du foie/thérapie , Antinéoplasiques/usage thérapeutique , Phénylurées/usage thérapeutique , Facteurs temps , Brésil/épidémiologie , Facteurs de risque , Résultat thérapeutique , Chimioembolisation thérapeutique/effets indésirables , Chimioembolisation thérapeutique/mortalité , Nicotinamide/analogues et dérivés , Carcinome hépatocellulaire/étiologie , Carcinome hépatocellulaire/mortalité , Carcinome hépatocellulaire/anatomopathologie , Charge tumorale , Estimation de Kaplan-Meier , Centres de soins tertiaires , Hépatectomie/effets indésirables , Hépatectomie/mortalité , Tumeurs du foie/étiologie , Stadification tumorale , Antinéoplasiques/effets indésirables
SÉLECTION CITATIONS
Détails de la recherche